• # LGM Pharma is a Filgrastim CAS# 121181-53-1 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Filgrastim
  • CAS #: 121181-53-1
  • Mode of Action:

    Filgrastim binds to the G-CSF receptor and stimulates the production of neutrophils in the bone marrow. As a G-CSF analog, it controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. Filgrastim also stimulates the release of neutrophils from bone marrow storage pools and reduces their maturation time. Filgrastim acts to increase the phagocytic activity of mature neutrophils. In patients receiving cytotoxic chemotherapy, Filgrastim can accelerate neutrophil recovery, leading to a reduction in duration of the neutropenic phase

  • Pharmacodynamics:

    Used in the treatment of chemotherapy-induced neutropenia by enhancing the production of neutrophils. Filgrastim acts on hematopoietic cells by binding to specific cell surface receptors thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. When tbo-filgrastim is administered to cancer patients, it took 3-5 days to reach maximum absolute neutrophil count (ANC). Levels of neutrophils returned to baseline by 21 days following completion of chemotherapy. In the healthy volunteer trials, doubling the tbo-filgrastim subcutaneous dose from 5 to 10 mcg/kg resulted in a 16-19% increase in the ANCmax and a 33-36% increase in the area under the effect curve for ANC.

  • IUPAC: Colony-stimulating factor (human clone 1034), N-L-methionyl-
  • ATC: L03AA02
  • DrugBank: DB00099 (BIOD00072, BTD00072)
  • Formula: C845-H1339-N223-O243-S9
  • Molecular Mass: 18798.7851
  • Synonyms: Biograstim, DRG-0086, Filgrastim, Filgrastim Hexal, Filgrastim ratiopharm, Filgrastim-sndz, Filgrastime, Filgrastime [INN-French], Filgrastimum, Filgrastimum [INN-Latin], Granulocyte colony stimulating factor, recombinant, Granulokine, hrG-CSF, HSDB 8159, KRN 8601, Leucostim, MBRI 9901, N-L-Methionylcolony-stimulating factor (human clone 1034), Neukine, Neupogen, Nivestim, Nufile-Safe, r-metHug-C-SF, r-metHug-CSF, Ratiograstim, Recombinant methionyl granulocyte colony stimulating factor, Recombinant methionyl human G-CSF, rG-CSF, rHG-CSF, Tevagrastim, UNII-PVI5M0M1GW, XM 02, Zarxio, Zarzio
  • AHFS Code: 20:16.0
  • General Reference:


    1. Wang B, Ludden TM, Cheung EN, Schwab GG, Roskos LK: Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers. J Pharmacokinet Pharmacodyn. 2001 Aug;28(4):321-42. Pubmed
    2. FDA label for Neupogen and tbo-filgrastim


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants


  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service